European CHMP recommends bevacizumab biosimilar (Onbevzi)
Onbevzi has comparable quality, safety and efficacy to Avastin (bevacizumab) and is intended for treatment of colon/rectal cancer, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer.
Source:
European Medicines Agency